These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 3935136)

  • 1. [Validation of parenteral drug production: benefits and costs].
    Tagliapietra L
    Boll Chim Farm; 1985 Jul; 124(7):285-92. PubMed ID: 3935136
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What is the cost of drug quality?].
    Hannse H
    Fortschr Med; 1975 Aug; 93(24):1083-4, 1112-3. PubMed ID: 818000
    [No Abstract]   [Full Text] [Related]  

  • 6. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Introduction to pharmaco-economics: 'glossary'].
    Auray JP
    Therapie; 2001; 56(2):89-91. PubMed ID: 11471379
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomics of adverse drug reactions.
    Lundkvist J; Jönsson B
    Fundam Clin Pharmacol; 2004 Jun; 18(3):275-80. PubMed ID: 15147278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THE ECONOMICS OF ADVERSE DRUG REACTIONS--case studies.
    Visconti JA; Smith MC
    Ann Pharmacother; 2006 Mar; 40(3):529-36. PubMed ID: 16507611
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug economics--a potent cure, but with the risk of adverse effects].
    Kristiansen IS
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):901-2. PubMed ID: 8191463
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceutical research: cost savings through innovation.
    Cohen KR; Levy RA
    AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacoeconomics. A new concept of an old practice].
    Palma-Aguirre JA
    Gac Med Mex; 1998; 134(5):621-4. PubMed ID: 9842147
    [No Abstract]   [Full Text] [Related]  

  • 14. Achieving a quality drug supply.
    Nelson G
    J Am Pharm Assoc; 1974 Oct; 14(10):548-9, 564. PubMed ID: 4420394
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical application of drugs with emphasis on more efficacy and lower costs].
    Xie H; Zhou H
    Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):3-4. PubMed ID: 7600317
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic evaluations of antifungal therapies.
    Hennen CR
    Curr Med Res Opin; 2009 Jul; 25(7):1751-8. PubMed ID: 19557894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.